Abstract: The invention relates to novel pharmaceutical compositions including, as active ingredient, an antibody binding the human anti-Müllerian hormone type II receptor (AMHR-II) and an anticancer agent, as well as the therapeutic applications of these compositions.
Type:
Grant
Filed:
October 25, 2016
Date of Patent:
January 15, 2019
Assignees:
LABOTATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES, ICM INSTITUT REGIONAL DU CANCER DE MONTPELLIER, I.N.S.E.R.M. (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER